MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$5,123K
EPS
-$2.01
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2025-03-31
Revenue
0 0 -
Research and development
2,205 3,298 2,364
General and administrative
2,708 3,623 3,097
Total operating expenses
4,913 6,921 5,461
Interest (expense) income
-212 -110 -84
Foreign exchange loss
2 -12 2
Total other (expense) income
-210 -122 -82
Net loss and comprehensive loss
-5,123 -7,043 -5,543
Unrealized loss on available-for-sale securities
-0 -
Total comprehensive loss
--7,043 -5,543
Earnings per share, diluted
-2.01 -2.76 -2.61
Net loss per share - basic
-2.01 -2.76 -2.61
Weighted-average common shares - basic
2,552,429 2,552,429 2,126,287
Weighted-average common shares - diluted
2,552,429 2,552,429 2,126,287
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss andcomprehensive loss-$5,123K Total other (expense)income-$210K Total operatingexpenses$4,913K Foreign exchange loss$2K Interest (expense)income-$212K General andadministrative$2,708K Research and development$2,205K

Aptose Biosciences Inc. (APTOF)

Aptose Biosciences Inc. (APTOF)